Literature DB >> 7518802

Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

K J Maloy1, A M Donachie, D T O'Hagan, A M Mowat.   

Abstract

We have examined the range of mucosal and systemic immune responses induced by oral or parenteral immunization with ovalbumin (OVA) entrapped in poly(D,L-lactide-co-glycolide) (PLG) microparticles. A single subcutaneous immunization with OVA-PLG primed significant OVA-specific IgG and delayed-type hypersensitivity (DTH) responses. The DTH responses were of similar magnitude to those obtained using immunostimulating complexes (ISCOMS) as a potent control adjuvant, although ISCOMS stimulated higher serum IgG responses. Both vectors also primed OVA-specific in vitro proliferative responses in draining lymph node cells following a single immunization and strong OVA-specific CTL responses were found after intraperitoneal (i.p.) immunization. ISCOMS were more efficient in inducing cytotoxic T lymphocytes (CTL), requiring much less antigen and only ISCOMS could stimulate primary OVA-specific CTL responses in the draining lymph nodes. Multiple oral immunizations with OVA in PLG microparticles or in ISCOMS resulted in OVA-specific CTL responses and again ISCOMS seemed more potent as fewer feeds were necessary. Lastly, multiple feeds of OVA in PLG microparticles generated significant OVA-specific intestinal IgA responses. This is the first demonstration that PLG microparticles can stimulate CTL responses in vivo and our results highlight their ability to prime a variety of systemic and mucosal immune responses which may be useful in future oral vaccine development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518802      PMCID: PMC1422380     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Biodegradable microparticles as controlled release antigen delivery systems.

Authors:  D T O'Hagan; D Rahman; J P McGee; H Jeffery; M C Davies; P Williams; S S Davis; S J Challacombe
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

2.  Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.

Authors:  A M Mowat; A M Donachie; G Reid; O Jarrett
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

3.  Macrophages as accessory cells for class I MHC-restricted immune responses.

Authors:  J E Debrick; P A Campbell; U D Staerz
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

Review 4.  ISCOMS--a novel strategy for mucosal immunization?

Authors:  A M Mowat; A M Donachie
Journal:  Immunol Today       Date:  1991-11

5.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

6.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

7.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.

Authors:  H Takahashi; T Takeshita; B Morein; S Putney; R N Germain; J A Berzofsky
Journal:  Nature       Date:  1990-04-26       Impact factor: 49.962

8.  Release of human serum albumin from poly(lactide-co-glycolide) microspheres.

Authors:  M S Hora; R K Rana; J H Nunberg; T R Tice; R M Gilley; M E Hudson
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

9.  Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens.

Authors:  A M Mowat; K J Maloy; A M Donachie
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

10.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  23 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 4.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

5.  Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy.

Authors:  Suzanne Foster; Craig L Duvall; Emily F Crownover; Allan S Hoffman; Patrick S Stayton
Journal:  Bioconjug Chem       Date:  2010-11-02       Impact factor: 4.774

Review 6.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

Review 7.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

Review 8.  The intestinal uptake of particles and the implications for drug and antigen delivery.

Authors:  D T O'Hagan
Journal:  J Anat       Date:  1996-12       Impact factor: 2.610

9.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models.

Authors:  Ruijiang Song; Shuqin Liu; Robert J Adams; Kam W Leong
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

Review 10.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.